About this Research Topic
Cellular interactions in the tumor microenvironment (TME) significantly govern cancer progression and drug response. In recent years, breakthroughs in biotechnology have led to identification of complex and unique biologic features associated with carcinogenesis. It provides numerous potential new targets on tumor cell itself or in TME, and the following possible new strategies for tumor precision therapy.
On the other hand, for drugs that are already on the market or in clinical trials, tumor and cell-free DNA profiling, immune markers, and proteomic and RNA analyses are used to identify these characteristics for optimization of anticancer therapy in individual patients. Consequently, two major strategies are being used for predicting clinically relevant tumor behaviors in precision oncology, such as treatment response and emergence of drug resistance: inference based on genomic, transcriptomic, epigenomic and/or proteomic analysis of patient samples, and phenotypic assays in personalized cancer avatars. The latter approach has historically relied on in vivo mouse xenografts and in vitro organoids. Recent advances already showed the accuracy of organoids in mimicking clinical tumor behaviors, and the first report on prospective clinical trial of organoids as predictors of patient outcome provided a proof of concept for the clinical value of drug response phenotypic testing. With further development of organoids, it is urgent to explore more with basic research techniques for their potential clinical applications.
In this Research Topic, we aim to 1)Collect original research and reviews on the recent progress in organoid technologies, which promote better understanding of tumor development mechanisms and the application value of organoids in personalized treatment.
2)Collect original research and reviews on tumor precision treatment, especially new methods, and novel targets in tumor microenvironment for tumor precision therapy and immunotherapy.
Potential topics include but are not limited to the following:
• Development of novel organoid techniques to offer spatial and temporal insights into cancer-immune/stromal cell interactions.
• The use of cancer organoids to study tumor progress mechanism or drug response. Identification of novel therapeutic targets for anti-cancer immunity
• Developing precision medicine with combinations of gene-targeted therapy with immune-targeted approaches (e.g., checkpoint blockade, personalized vaccines and/or chimeric antigen receptor T-cells), hormonal therapy, chemotherapy and/or novel agents.
Please note: studies consisting solely of bioinformatic investigation of publicly available genomic/transcriptomic/proteomic data do not fall within the scope of the section unless they are expanded and provide significant biological or mechanistic insight into the process being studied and will not be accepted as part of this Research Topic.
On the other hand, for drugs that are already on the market or in clinical trials, tumor and cell-free DNA profiling, immune markers, and proteomic and RNA analyses are used to identify these characteristics for optimization of anticancer therapy in individual patients. Consequently, two major strategies are being used for predicting clinically relevant tumor behaviors in precision oncology, such as treatment response and emergence of drug resistance: inference based on genomic, transcriptomic, epigenomic and/or proteomic analysis of patient samples, and phenotypic assays in personalized cancer avatars. The latter approach has historically relied on in vivo mouse xenografts and in vitro organoids. Recent advances already showed the accuracy of organoids in mimicking clinical tumor behaviors, and the first report on prospective clinical trial of organoids as predictors of patient outcome provided a proof of concept for the clinical value of drug response phenotypic testing. With further development of organoids, it is urgent to explore more with basic research techniques for their potential clinical applications.
In this Research Topic, we aim to 1)Collect original research and reviews on the recent progress in organoid technologies, which promote better understanding of tumor development mechanisms and the application value of organoids in personalized treatment.
2)Collect original research and reviews on tumor precision treatment, especially new methods, and novel targets in tumor microenvironment for tumor precision therapy and immunotherapy.
Potential topics include but are not limited to the following:
• Development of novel organoid techniques to offer spatial and temporal insights into cancer-immune/stromal cell interactions.
• The use of cancer organoids to study tumor progress mechanism or drug response. Identification of novel therapeutic targets for anti-cancer immunity
• Developing precision medicine with combinations of gene-targeted therapy with immune-targeted approaches (e.g., checkpoint blockade, personalized vaccines and/or chimeric antigen receptor T-cells), hormonal therapy, chemotherapy and/or novel agents.
Please note: studies consisting solely of bioinformatic investigation of publicly available genomic/transcriptomic/proteomic data do not fall within the scope of the section unless they are expanded and provide significant biological or mechanistic insight into the process being studied and will not be accepted as part of this Research Topic.
Keywords: Cancer, organoid, precision medicine, tumor immunotherapy, tumor microenvironment
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
